TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Allergan Attracts Bearish Position optionMONSTER submits: By David Russell Allergan (AGN) attempted to rally against a short-term downtrend, prompting one trader to bet against the stock Friday.Complete Story » seekingalpha.com |
Exelixis Gets a Compound Back Derek Lowe submits: Exelixis (EXEL) has long been a bit of a puzzle to outside observers. The company has developed a number of clinical candidates in oncology (many of them kinase inhibitors, I believe). In fact, for a while there, they seemed to have developed more clinical candidates than a company that size should have been able to manage. It was a bit alarming to employees of larger companies in the area. And figuring out what the structures of these things were wasn't so easy, either. I once had the unenviable assignment of trying to break down a stack of their patent applications to see if I could find the lead structure for one of their compounds, and after a week or so I had to concede. None of my usual tricks worked - untangling and charting out the synthetic pathways from the experimental section to see the common threads, looking for sudden upticks in the amounts of intermediates or final compounds being prepared, looking to see if some compounds had been more completely characterized than others, and so on. No, these folks had done a fine job of sweeping up after themselves, and over the years I've run into other people who came to the same conclusion.Complete Story » seekingalpha.com |
Gilead Sciences, Inc. Q2 2010 Earnings Call Transcript Gilead Sciences, Inc. (GILD)Q2 2010 Earnings Call TranscriptJuly 20, 2010 5:00 pm ETComplete Story » seekingalpha.com |
Three Chinese Companies Line Up Hong Kong IPOs China's Winsway Coking Coal began pre-marketing a $1 billion IPO in Hong Kong, while two other mainland firms launched investor presentations for IPOs aiming to raise up to US$845 million combined. online.wsj.com |
Sanofi Continues to Look Beyond Its Own Walls to Fill the Void From Drugs Going Off-Patent The Burrill Report submits: By Daniel S. Levine “A key strategy for Sanofi-Aventis (SNY) is to transform its R&D model and discover new medicines through the use of novel technologies and innovative partnerships," says Marc Cluzel, executive vice president of research and development for Sanofi.If you want to know what Big Pharma will look like in ten years, Sanofi-Aventis may hold the answer. The French pharmaceutical giant entered into a ten-year agreement with Covance (CVD), a contract research organization, for up to $2.2 billion as it continues to outsource research and development.Complete Story » seekingalpha.com |